Natixis Advisors L.P. Has $11.11 Million Stock Position in Quest Diagnostics Incorporated (NYSE:DGX)

Natixis Advisors L.P. boosted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 47.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,601 shares of the medical research company's stock after purchasing an additional 25,847 shares during the quarter. Natixis Advisors L.P. owned about 0.07% of Quest Diagnostics worth $11,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of DGX. Czech National Bank increased its stake in Quest Diagnostics by 0.4% during the fourth quarter. Czech National Bank now owns 19,692 shares of the medical research company's stock worth $2,715,000 after purchasing an additional 75 shares during the period. Mendota Financial Group LLC increased its position in Quest Diagnostics by 6.2% during the 4th quarter. Mendota Financial Group LLC now owns 1,296 shares of the medical research company's stock worth $179,000 after purchasing an additional 76 shares in the last quarter. Montecito Bank & Trust lifted its position in Quest Diagnostics by 4.7% during the fourth quarter. Montecito Bank & Trust now owns 1,909 shares of the medical research company's stock worth $263,000 after buying an additional 85 shares during the period. Naples Global Advisors LLC boosted its holdings in Quest Diagnostics by 1.5% in the fourth quarter. Naples Global Advisors LLC now owns 6,171 shares of the medical research company's stock valued at $851,000 after acquiring an additional 90 shares during the last quarter. Finally, State of Michigan Retirement System boosted its position in shares of Quest Diagnostics by 0.3% in the fourth quarter. State of Michigan Retirement System now owns 33,417 shares of the medical research company's stock worth $4,608,000 after buying an additional 100 shares during the period. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Stock Down 0.6 %

Shares of DGX stock traded down $0.79 during mid-day trading on Wednesday, hitting $136.15. The stock had a trading volume of 612,346 shares, compared to its average volume of 1,051,337. The firm's 50-day moving average is $130.73 and its two-hundred day moving average is $132.01. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.97 and a quick ratio of 0.89. The firm has a market capitalization of $15.12 billion, a P/E ratio of 18.43, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. Quest Diagnostics Incorporated has a 12-month low of $119.59 and a 12-month high of $145.58.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.86 by $0.18. The company had revenue of $2.37 billion during the quarter, compared to analysts' expectations of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. Quest Diagnostics's quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.04 EPS. On average, analysts predict that Quest Diagnostics Incorporated will post 8.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DGX has been the topic of several recent research reports. Truist Financial raised their price target on Quest Diagnostics from $145.00 to $150.00 and gave the stock a "hold" rating in a report on Wednesday, April 24th. SVB Leerink initiated coverage on shares of Quest Diagnostics in a research report on Monday, February 26th. They set a "market perform" rating and a $135.00 price objective on the stock. StockNews.com downgraded Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Friday, May 3rd. Leerink Partnrs reissued a "market perform" rating on shares of Quest Diagnostics in a research note on Monday, February 26th. Finally, UBS Group raised their price objective on shares of Quest Diagnostics from $139.00 to $146.00 and gave the company a "neutral" rating in a research report on Wednesday, April 24th. Ten equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $146.17.

Insiders Place Their Bets

In related news, SVP Michael E. Prevoznik sold 5,611 shares of the company's stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $125.88, for a total transaction of $706,312.68. Following the transaction, the senior vice president now owns 38,478 shares of the company's stock, valued at $4,843,610.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Michael E. Prevoznik sold 5,611 shares of Quest Diagnostics stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total transaction of $706,312.68. Following the transaction, the senior vice president now owns 38,478 shares in the company, valued at approximately $4,843,610.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael E. Prevoznik sold 661 shares of the firm's stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $126.14, for a total transaction of $83,378.54. Following the transaction, the senior vice president now directly owns 40,206 shares of the company's stock, valued at $5,071,584.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,910 shares of company stock valued at $2,159,602. 0.79% of the stock is owned by corporate insiders.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.